Roviello Giandomenico, Corona Silvia Paola, Bonetta Alberto, Cappelletti Maria Rosa, Generali Daniele
Medical Oncology Unit, Department of Oncology, San Donato Hospital, Arezzo.
Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
Onco Targets Ther. 2017 Jul 31;10:3811-3815. doi: 10.2147/OTT.S143020. eCollection 2017.
The aim of this study was to evaluate the correlation between circulating tumor cells (CTCs) and patterns of recurrence in patients with hormone-sensitive prostate cancer. The study involved patients with histologically confirmed, advanced prostatic adenocarcinoma, who were tested for CTCs (Veridex) when they developed recurrence after radical prostatectomy or external beam radiation between 2008 and 2014. Forty-two prostate cancer patients were evaluated. CTCs were detected in 14 out of 42 (33.3%) patients (Group A), while the remaining 28 (66.7%) showed undetectable levels of CTCs (Group B). The mean prostate-specific antigen value was higher in Group A in comparison to Group B (6.2 vs 3.3 ng/dL) (=0.48). Presence of bone metastases alone or along with nodal metastases was more common in Group A (57.1%) in comparison to Group B (25%) (=0.04). In a univariate analysis, the presence of CTCs at diagnosis correlated with the development of bone recurrence (OR: 4; 95% CI: 1.0-15.9; =0.05). Even if the study enrolled only a small number of patients, the detection of CTCs in the blood appears to correlate with the pattern of progression in patients with hormone-sensitive prostate cancer, suggesting a possible role in anticipating recurrence at the bone in men with higher tumor load. Further prospective studies are warranted in this setting.
本研究的目的是评估激素敏感性前列腺癌患者循环肿瘤细胞（CTC）与复发模式之间的相关性。该研究纳入了经组织学确诊的晚期前列腺腺癌患者，这些患者在2008年至2014年期间接受根治性前列腺切除术或体外照射后出现复发时接受了CTC检测（Veridex）。对42例前列腺癌患者进行了评估。42例患者中有14例（33.3%）检测到CTC（A组），其余28例（66.7%）CTC水平未检测到（B组）。A组的平均前列腺特异性抗原值高于B组（6.2对3.3 ng/dL）（P=0.48）。与B组（25%）相比，A组单独出现骨转移或伴有淋巴结转移的情况更为常见（57.1%）（P=0.04）。在单因素分析中，诊断时CTC的存在与骨复发的发生相关（OR：4；95%CI：1.0-15.9；P=0.05）。即使该研究仅纳入了少数患者，但血液中CTC的检测似乎与激素敏感性前列腺癌患者的进展模式相关，这表明其在预测肿瘤负荷较高男性的骨复发方面可能发挥作用。在这种情况下，有必要进行进一步的前瞻性研究。
